Table 5.

Summary of the real-world experience using oritavancin for microbiologically positive osteomyelitis

Study	Patient background	Pathogens	Oritavancin dose and duration	Outcome	Adverse effects
Schulz et al. [32]	4 patients; median age 59 years (31–76); 25% male	MSSA	3 patients: 1200 mg × 1 dose, then 800 mg weekly ≥ 2 doses 1 patient: 1200 mg × 2/week	Success × 2 Improvement × 2	Anemia and leukopenia in 1 patient
Chastain et al. [36]	12 patients, median age 65 years (47–79), 67% male, 67% DM	MRSA	3 patients = 1200 mg × 1 dose 9 patients = 1200 mg × ≥ 2 doses	100% Success	None
Foster et al. [37]	57 y/o M with osteomyelitis secondary to prosthetic hip replacement	Daptomycin non-susceptible VRE	1200 mg once weekly × 6 weeks	Success	None
Delaportas et al. [31]	49 y/o F with right tibial osteomyelitis secondary to retained intramedullary nail	MSSA	1200 mg once weekly × 6 weeks	Success	None
Ruggero et al. [33]	46 y/o M with native vertebral osteomyelitis	MRSA	1200 mg every 2 weeks × 4 doses, then 1200 mg 1 month later	Improvement	None
Dahesh et al. [35]	59 y/o M with hardware-associated vertebral osteomyelitis	Vancomycin-resistant and daptomycin NS E. faecium	1200 mg weekly × 2 doses, then 800 mg weekly × 8 doses	Improvement	None
Stewart et al. [34]	26 y/o F with sacral joint osteomyelitis; IVDU	MSSA	1200 mg × 1 dose	Failure	None
CHROME Registry [38]	18 patients; mean age 58.4 years, 38.9% male, 77.8% prior antibiotics, 50% failure prior antibiotics	MRSA, MSSA, coagulase-negative Staphylococcus, E. faecalis, E. faecium, S. pyogenes	10 patients = 1200 mg × 1 dose 8 patients = 1200 mg × ≥ 2 doses	Clinical success: Single dose: 90% Multi-dose: 87.5%	Moderate, not serious infusion-related reaction (in multidose patient)

M male, F female, y years, MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, VRE vancomycin-resistant Enterococcus, NS non-susceptible, DM diabetes mellitus, IVDU intravenous drug user